Company Description
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases.
The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.
Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial.
It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease.
The company was incorporated in 2015 and is based in New York, New York.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 419 |
| CEO | Dr. Alexandria Forbes Ph.D. |
Contact Details
Address: 450 East 29th Street, 15th Floor New York, New York 10016 United States | |
| Phone | (646) 490-2965 |
| Website | meiragtx.com |
Stock Details
| Ticker Symbol | MGTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001735438 |
| CUSIP Number | G59665102 |
| ISIN Number | KYG596651029 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexandria Forbes Ph.D. | Chief Executive Officer, President and Director |
| Richard Brian Giroux B.A. | Chief Operating Officer and Chief Financial Officer |
| Dr. Stuart Naylor Ph.D. | Chief Development Officer |
| Robert J. Wollin J.D. | General Counsel and Secretary |
| Dr. Michel Michaelides M.D. | Head of Clinical Ophthalmology |
| Christine Elise Sheehy | Senior Vice President of Global Integration |
| Tim Randall | Senior Vice President of Risk and Internal Controls |
| Dr. Alastair Leighton Ph.D. | Senior Vice President of Manufacturing and Supply Chain |
| Dr. Robert K. Zeldin M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 8-K/A | [Amend] Current report |
| Mar 15, 2024 | 10-K | Annual Report |
| Mar 14, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | 8-K | Current Report |
| Feb 9, 2024 | SCHEDULE 13G | Filing |
| Feb 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 29, 2023 | EFFECT | Notice of Effectiveness |
| Dec 21, 2023 | S-3 | Registration statement under Securities Act of 1933 |